Updated:
Xtant Medical
Xtant Medical operates from Belgrade, Montana, tracing its lineage to research spun out of Montana State University's Center for Biofilm Engineering.
Xtant Medical
Xtant Medical operates from Belgrade, Montana, tracing its lineage to research spun out of Montana State University's Center for Biofilm Engineering. The firm functions as both a regulated tissue bank and a manufacturer of spinal fixation hardware, a dual identity that shapes its commercial posture. It processes donated human tissue into orthobiologic grafts while designing cervical, thoracolumbar, and interbody implant systems meant to be used alongside those grafts. The firm's strategy centers on vertical integration in the orthobiologics supply chain. On the biologics side, Xtant runs donor recovery, processing, and distribution from its Montana facility, using patented technologies such as BacteRinse to preserve growth factors. Its implant portfolio includes the Cortera, CervAlign, and Fortilink-TS systems, all engineered to pair with its own biologics. The product catalog lists standalone graft offerings like OsteoFactor Pro and Trivium. The firm sells primarily into the US spinal surgery market, supplying surgeons who perform complex, deformity, and degenerative procedures. Xtant maintains a single headquarters in Belgrade, Montana, without disclosed satellite offices. It operates an OEM channel alongside its branded business. The firm marks National Donate Life Month and Blue & Green Day annually, reinforcing its tissue-bank identity. September 2024: Sean Browne was appointed President and CEO, joining from Alpha Biomedix, a regenerative medicine company (per the firm, September 2024). The firm's structural differentiator is its dual identity as both a tissue bank and an implant manufacturer: it controls the donor-to-distribution chain for biologics while supplying the hardware that sits alongside those grafts in the operating room. This integrated model creates a single-source proposition for surgeons who would otherwise manage separate biologic and implant vendor relationships.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Belgrade
Corporate office
664 Cruiser Lane, Belgrade, MT 59714, United States
Sector focus
Frequently asked questions
Is Xtant Medical a tissue bank or a device company?
It is both. Xtant operates a regulated tissue bank that recovers, processes, and distributes donated human tissue into orthobiologic grafts. It also designs and sells a portfolio of spinal implant hardware, including cervical, thoracolumbar, and interbody systems, which are engineered to work together with its biologics.
How does Xtant source the human tissue for its biologics?
Xtant runs its own donor recovery and processing operations, which it describes as vertically integrated — from donor screening through final distribution. The firm emphasizes traceability and quality control inside its Montana facility, but does not publicly disclose recovery network partners or geographic catchment.
What implant systems does Xtant currently offer?
Named systems on its website include Cortera, CervAlign, and Fortilink-TS with Tetrafuse 3D Technology. These cover cervical and thoracolumbar applications and are positioned as complementary to Xtant's own biologics line.
Does Xtant Medical have a public-market listing?
Yes, Xtant Medical Holdings trades publicly on the NYSE American exchange under the ticker XTNT. Its operating subsidiary is Xtant Medical, the tissue bank and implant manufacturer.
Who runs investment and operational decisions at Xtant?
Sean Browne was appointed President and CEO in September 2024, succeeding a prior leadership tenure. The firm has not disclosed a separate CIO or investment committee structure, consistent with an operating company that deploys capital through internal R&D, manufacturing, and sales rather than a fund model.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: